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James GiordanoIntroduction
Prof. James Giordano is Chief of the Neuroethics
Studies Program in the Center for Clinical Bioethics,
and is on the faculty of the Division of Integrative
Physiology, and Graduate Liberal Studies Program at
Georgetown University, Washington, DC, USA. He is
Clark Fellow in Neurosciences and Ethics at the Human
Science Center of Ludwig-Maximilians Universität,
Munich, Germany, is 2012–2014 William H. and Ruth
Crane Schaefer Distinguished Visiting Professor of
Neuroethics at Gallaudet University, Washington, DC,
and is also a Senior Fellow of the Potomac Institute for
Policy Studies - a Washington-DC area think tank dedi-
cated to the assessment of emerging developments in
science and technology, and the ethico-legal and social
issues they foster (Figure 1).
As a neuroscientist and neuroethicist, his ongoing re-
search includes the neuroethics of pain research and treat-
ment, and also focuses upon the ways that neuroscience
and neurobiotechnology research are conducted in various
cultures. Prof. Giordano's work addresses the potential for
leveraging scientific and technologic power in - and over -
marginalized populations, and the possibility to exert
"biopower" through neuroscientific and neurotechnological
capability in regional and global economics and social
structures. Also, Prof Giordano's studies assess the limita-
tions of neuroscience and neurotechnology, the persistent
unknowns inherent to neuroscientific research, and the
problems of informed consent and obtaining clinical equi-
poise when utilizing these approaches in clinical practice.
His research group is working to both evaluate the validity
and value of existing approaches to neuroethics, and to en-
gage discourse toward developing a more cosmopolitan ap-
proach to neuroethics that reflects, and could be viable for
use in the evermore diverse world-culture of the 21st
century.Correspondence: jgiordano@neurobioethics.org
Center for Clinical Bioethics, Georgetown University Medical Center, 4000
Reservoir Road, Washington, DC 20057, USA
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reproduction in any medium, provided the orIn this Q&A, we talk to Prof. Giordano about some of
the most important ethical problems that should be con-
sidered when conducting biomedical research in all types
of clinical settings, with particular emphasis on some of
the main challenges of research in low-and-middle-in-
come countries.
The podcast for this interview is available at: http://www.
biomedcentral.com/sites/2999/download/Giordano.mp3.
Edited transcript
1. What, in your opinion, are the most important
ethical considerations that need to be taken into ac-
count when conducting medical research that in-
volves human interventions in particular?
In many ways, this question evokes the spirit of bioeth-
ics as first described by philosopher Fritz Jahr some 87 -
years ago. Jahr's concept, based in part upon the work of
his contemporary, the physician/philosopher Albert
Schweitzer, and derived, at least to some extent from the
ideas of Immanuel Kant, was to treat living beings as
ends unto themselves, and not merely as means (to the
acquisition of information, and knowledge, etc.). Clearly,
this harkens to the tenor of the Nuremberg Code, the
Declaration of Helsinki, and the Belmont Report. Taken
together with the subsequent work of Tom Beauchamp,
and colleague James Childress, these documents con-
cretized the core maxims of beneficence, non-harm, and
respect for the autonomy of those who are the subjects
of research. While the specific question addresses hu-
man research, mention must be made of core principles
of beneficence and non-harm in animal research as well
- a point becoming ever more relevant in light of an in-
creasing body of neuroscientific research that is demon-
strating the cognitive capacity of animals, and the use of
neurocentric criteria as the basis of moral regard and
treatment of non-human organisms (both in research,
and more generally in a variety of other contexts, such
as companion animals, livestock, etc.). This is the focus
of the work of Sherry Loveless of our group, who is col-
laborating with colleagues from the Animal Behavioral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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New York to articulate a more finely-grained (neuro)eth-
ics of animal welfare and care. A number of papers in
Philosophy, Ethics and Humanities in Medicine have
addressed the ethics of animal research, as well.
But, to return to the main issue of human experimen-
tation - and particularly clinical trials, the key issues cen-
ter upon the notion of "good" that is derived from
research. We can view science as one of the major pillars
of medicine, with research - and perhaps most import-
antly in the contemporary view, the clinical trial - as the
fundamental "tool" with which to acquire scientific
knowledge and technical capability. In this way, biomed-
ical science fortifies the knowledge-base and technical
capabilities of medicine, and by extension, is instrumen-
tal to the achievement of the fundamental goods of
health, wellness and a lessening of the human predica-
ment of injury, disease, illness and suffering.
But here it is important to note that the other pillar of
medicine is humanitarian consideration and care. I am
fond of quoting Edmund Pellegrino's claim that medicine
is ". . .the most humanitarian endeavour of the sciences,
and the most scientific endeavour of the humanities".
Indeed, medicine - and the science that serves it - is fo-
cused upon the primacy of the good of the person who is
the patient. It becomes evident that any discussion of the
"good" opens a Pandora's Box when attempting to definewhat this means in and between peoples, groups and cul-
tures. In clinical research, the (basic) goods and the explicit
goals are to generate information necessary to address
questions about the nature of a disease, injury and/or ill-
ness; if and how a treatment works, in whom, under what
conditions, and ultimately, to effect some therapeutic bene-
fit - and to avoid or lessen harms and burdens - to the pop-
ulations represented by those studied. Yet, questions,
issues and problems arise relative to who should be in-
cluded in research, methods of groups selection, distribu-
tion of treatments to those studied, and openness in
defining the parameters of the study, its benefits and risks.
Of particular emphasis is the notion of informed consent,
given the novelty - and in many cases uncertainty - of spe-
cific cutting-edge interventions and technologies. This then
generates concerns about asymmetries - and inequities - of
power that exist between those conducting (and funding)
research, and those that are participating subjects, the eco-
nomic - and in some cases political - forces that may create
pulling trends over the scope, conduct and allocation of
scientific and medical studies, goods and resources, and
how these power dynamics must be addressed, and bio-
medical research and its translational provisions defined,
guided, and governed - both by ethics and through well-
informed policy.
2. Does medical research in low-and-middle-income
countries present specific ethical challenges?
Very much so. The populations of developing and non-
developed countries are often profoundly affected by the
plight of disease, injury and impoverishment. These pop-
ulations have dire need for modern medical care. At face
value, this two-fold circumstance of high morbidity and
strong need could be viewed as well-defined opportun-
ities to engage research trials of existing interventions (for
example, types of comparative effectiveness studies), and
new developments in biomedical techniques, tools and
technologies. In many cases, this is, in fact, correct. How-
ever, it is important to examine the asymmetrical relation-
ships that exist under these conditions. While it could be
assumed that conducting research in and with these popu-
lations would provide some appreciable benefit to those
studied, the question arises whether the beneficial results,
outcomes and products of such research will be afforded
to these populations, to what extent, and at what cost(s)?
Obviously, a major concern is whether the interven-
tions, goods and services will be sustainable in the host
country. Ideally, this would be the case. Yet, if such sus-
tainability involves the provision of goods, resources
and/or services by a developed country (rather than a
more microeconomically-sensitive sustainability that fos-
ters production and delivery of such goods and re-
sources by the host country itself ), then inter-dependency
is generated. This can create what French philosopher
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of biological factors to evoke dominance and or incur de-
pendence. When incurred on a national scale, this is con-
sidered to be a form of "biopolitics", in which the schism
(s) between "have" and "have not" countries is economic-
ally, socially, and politically manipulated.
The real question then, is how to engage research in
these populations, with these populations and for these
populations in ways that are sustainable, and at the same
time, supportive of the economic infrastructure of the re-
search enterprise. My colleague, economist and sociologist
Roland Benedikter of Stanford University, and I have
attempted to address these issues, and define potential
systems of conducting research that is macroeconomically
stable, yet sensitive to and supportive of microeconomic
variables and the need for non-dependent sustainability.
One of the persistent problems in any such approach is
the nature of global markets to move toward supply side
dynamics, and the lure of macroeconomic power capabil-
ity. Increasingly, this is not solely the province of Western
nations, but is becoming a more globally relevant variable,
given the rise of scientific and technological capabilities of
countries such as China, India, and Korea, and the ability
of (non-state) individual actors and venture capital groups
to develop viable "stakes" in the bioscience and technology
markets and at international bargaining tables.
Thus, I believe that we are facing what Professor
Benedikter refers to as "A New Global Shift" in the
power-dynamics of the 21st century, and biomedicine
will play an important role in defining the power bal-
ances of this new order. This imparts even greater
responsibility to maintain a culturally-sensitive ethical
framework for research as the balance of power moves
to a more widely distributed domain that is more prom-
inently influenced by non-western cultures, philosophies,
needs, values, and ideals. Working in our group, Misti
Ault Anderson is specifically addressing what this "Glo-
bal Shift" may mean for the scope, conduct, and transla-
tion of biomedical research upon such a progressively
more pluralist world-stage.
3. You mentioned that because of cultural and regional
differences, research procedures - such as assuring in-
formed consent - can become more complex. How so?
As previously mentioned, research is being conducted -
and highly scrutinised - in a number of developing and
non-developed countries. Moreover the contexts of such
research are changing. Thus, there is a need to address
not only nations and cultures' needs, values and mores,
but those ethical ideals and systems that are operative in
the countries and cultures in which said research is be-
ing undertaken. So, while it is important to ensure that
research is conducted ethically, an equally- if not more -
important question is "by which ethical standards?" Priorstudies by Adriana Petryna support that not attending to
variance in cultural values and ethics can deepen in-
equalities and inequities, and may incur a host of ethical
transgressions. Misti Ault Anderson and I have argued
that this diversity demands more than superficial appre-
ciation of differing ethical concepts and practises, as
there are real risks of adverse consequences if such
socio-cultural considerations in the conduct of research
are not fully appreciated and recognised. On one hand is
the risk of assuming an exclusively western stance, and
in so doing committing ethical imperialism. On the
other, there is risk of ethical relativism, in treating all sit-
uations as prima facie contingencies. We believe that
both situations risk incurring forms of biopower - in the
first instance through cultural dominance, and in the
second, through laissez faire practices that could over-
look certain violations of fundamental goods and human
rights simply for economic gain.
Balancing the need for cultural sensitivity and defined
ethical guidance demands re-examination of extant
ethical systems, principles and codes. Working with
philosopher John Shook of the University of Buffalo, and
Ernst Pöppel of the Ludwig Maximilians University,
Munich, Germany, our group is attempting to develop a
system of ethical analysis and revision in order to allow
a more cosmopolitan approach that regards anthropo-
logical similarities and distinctions, standpoints and
dialectic re-address and re-formulation of the moral
constructs and standards necessary to inform research
and the policies that guide and govern its applications in
and across cultures. Needless to say, this remains a
work-in-progress.
4. Many clinical researchers are required to work
closely with pharmaceutical companies in order to fa-
cilitate research. Some argue this introduces a con-
flict of interest, while others may argue that as long
as they are transparent about such associations, this
is not a true conflict. What are your views on this?
I would assert that the issue here is not simply limited
to associations with pharmaceutical companies. While
so-called "big pharma" has been strongly criticised for
directionally influencing the conduct and outcomes of
research, I think that it's unwise to throw away the baby
with the bathwater. Unrestricted corporate grants can- and
have - been important and instrumental to conducting and
supporting research that has led to a number of significant
and valuable findings and products. Yes, ethical improbity
has occurred in a number of research scenarios, but the
pharma-academic association is not unique in this regard.
Be that as it may, there is a crucial lesson to be learned
from the scrutiny of, and re-posturing toward pharmaceut-
ical support of academic research. Namely, it has prompted
increased diligence in assessing and reporting conflicts of
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that conjoins the academic, commercial and govern-
mental sectors (what has become known as the "triple
helix" of the contemporary scientific and technological
research enterprise).
This is important given the very real circumstances of
shrinking federal research funding (in light of continuing
resolutions and a potential sequestration crisis). Private
foundations and the commercial sector can and likely
will fill the gap generated by the decrease, if not loss, of
federal subsidies. I do not see this as negative; to the
contrary, I believe, or perhaps more accurately hope, that
this will compel a revision in the way(s) that research is
approached and executed. To be sure, there has been de-
fensible criticism against research endeavours that were
overly agnostic, or aimed solely at large scale market
shares. A revisionist stance could re-direct research to-
ward obtaining more "medicine-based evidence", and de-
veloping outcomes, techniques and products that translate
into care for smaller, more focused market sectors. This
would marry well with incentives for personalised medi-
cine. Yet, there is an equally defensible argument against
corporate funding of academic research in that it is seen
as "purloining" the integrity of the work, and inducing co-
ercive influence in the scope and outcomes of the results.
In principle this is a valid concern. However, scrutiny and
insights gained over the past decade have levied against
this situation. It may be that from these ashes may rise a
phoenix that positions the commercial sector to more dili-
gently support academic research, and in so doing, allow
for sustained engagement and innovation through these
times of economic hardship.
5. How can editors as well as clinical researchers en-
sure that all medical research is conducted ethically?
I see editors as collaborative partners, working with
IRBs and researchers, to ensure quality reporting and
dissemination of findings, ideas and critique. I like to
tell my students that scholarship is one of the only fields
in which one is "guilty until proven innocent". The peer-
review and editorial process establishes this gauntlet of
demonstration of "innocence" that the work, as reported
passes the muster of skepsis and scrutiny. The require-
ment for authors to affirm that any and all research was
conducted with IRB approval, and in accordance with
internationally accepted guidelines and standards repre-
sents a major step in re-grounding researchers' respon-
sibility for the ethical conduct of their work. While
good reviewers often cite apparent problems in the eth-
ical aspects of a particular study, editorial diligence and
responsibility cannot be lax. In many ways, the editor
serves as the first - and perhaps final - threshold that
must be crossed when evaluating the potential ethical
conduct of research as reported in a given manuscript.Of course, there will always be variation in the quality of
papers, and results. Yet, I think that the open access for-
mat is an asset in that it creates a more extensive forum
for the dissemination of findings, and in this way, enables
a larger audience of both readership and criticism.
6. You are a neuroscientist and neuroethicist. What
do you see as the major ethical issues in neuroscien-
tific research at present?
Neuroscientific and neurotechnological research incur
all of the same ethical issues as any other discipline of
cutting edge biomedical science: protection of subjects,
consent, conflicts of interest, are all germane to the re-
sponsible conduct of neuroscientific studies. However, I
think that neuroscience evokes a number of unique is-
sues and questions that reflect the nature and focus of
the field itself. First, I see these as stemming from the as
yet unanswered, so-called hard question or problem of
the field, namely how consciousness or mind occurs in
brain. Second, I see ethical issues spawned by the inter-
section of unknowns: how the brain actually functions
(on the level of efficient causality), the nature of normal-
ity and abnormality, the novelty of various techniques
and technologies, and how these techniques and technolo-
gies affect the structure and function of the brain to exert
effects (in treatments, enhancements, etc.). Third, are
those ethical issues generated by the use and/or misuse of
neuroscience and neurotechnologies in a range of social
applications, including medicine, the public sphere - to
change norms, standards, values and human relationships,
and in national security and defense.
The fundamental ethical questions are what should we
do with all the neuroscientific knowledge and capabil-
ities we possess, and what should we do about the
knowledge and capabilities we lack? This speaks directly
to what is sometimes referred to as the "first-tradition"
of neuroethics: the study of the possible neurological
bases of morality, ethics and relational beliefs and ac-
tions. In this way, neuroethics may be seen as a type of
meta-ethics that can help to understand how and why
we have certain moral cognitions, beliefs and develop
particular ethical systems for guiding our actions. But,
then we must ask - can neuroscience and its technolo-
gies actually afford this knowledge, and if so, how should
we use this knowledge to affect the human condition?
Obviously, I'll be at this for a while. . .these are not easy
questions, and there are no simple answers.
7. Where can I find out more?
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